BIOLASE, Inc.
BIOL · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $49,164 | $48,462 | $39,188 | $22,780 |
| % Growth | 1.4% | 23.7% | 72% | – |
| Cost of Goods Sold | $32,440 | $32,551 | $22,659 | $16,607 |
| Gross Profit | $16,724 | $15,911 | $16,529 | $6,173 |
| % Margin | 34% | 32.8% | 42.2% | 27.1% |
| R&D Expenses | $6,004 | $7,265 | $6,048 | $3,695 |
| G&A Expenses | $10,216 | $12,309 | $11,258 | $9,772 |
| SG&A Expenses | $28,657 | $33,984 | $26,597 | $21,014 |
| Sales & Mktg Exp. | $18,441 | $21,675 | $15,339 | $11,242 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $34,661 | $41,249 | $32,645 | $24,709 |
| Operating Income | -$17,937 | -$25,338 | -$16,116 | -$18,536 |
| % Margin | -36.5% | -52.3% | -41.1% | -81.4% |
| Other Income/Exp. Net | -$2,664 | -$3,187 | $23 | $1,835 |
| Pre-Tax Income | -$20,601 | -$28,525 | -$16,093 | -$16,701 |
| Tax Expense | $31 | $109 | $65 | $128 |
| Net Income | -$20,632 | -$28,634 | -$16,158 | -$16,829 |
| % Margin | -42% | -59.1% | -41.2% | -73.9% |
| EPS | -16.14 | -413.19 | -273.41 | -688.19 |
| % Growth | 96.1% | -51.1% | 60.3% | – |
| EPS Diluted | -16.14 | -413.19 | -273.41 | -688.19 |
| Weighted Avg Shares Out | 1,278 | 69 | 59 | 24 |
| Weighted Avg Shares Out Dil | 1,278 | 69 | 59 | 24 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2,361 | $2,749 | $2,224 | $2,359 |
| Depreciation & Amortization | $2,798 | $497 | $400 | $499 |
| EBITDA | -$15,442 | -$25,279 | -$13,469 | -$13,843 |
| % Margin | -31.4% | -52.2% | -34.4% | -60.8% |